These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15341882)

  • 1. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
    Faithfull S; Deery P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S54-62. PubMed ID: 15341882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of capecitabine (Xeloda) for cancer nursing practice.
    Gerbrecht BM; Kangas T
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S63-71. PubMed ID: 15341883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
    Sternberg CN; Reichardt P; Holland M
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences.
    MacLeod A; Branch A; Cassidy J; McDonald A; Mohammed N; MacDonald L
    Eur J Oncol Nurs; 2007 Jul; 11(3):247-54. PubMed ID: 17188937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vital role of education and information in patients receiving capecitabine (Xeloda).
    Chau I; Legge S; Fumoleau P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S41-53. PubMed ID: 15341881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
    Marsé H; Van Cutsem E; Grothey A; Valverde S
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S16-30. PubMed ID: 15341879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral capecitabine (Xeloda) in cancer treatment.
    Doyle DP; Engelking C
    Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
    [No Abstract]   [Full Text] [Related]  

  • 8. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
    Szetela AB; Gibson DE
    Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Canadian experience with capecitabine: partnering with patients to optimize therapy.
    Gerbrecht BM
    Cancer Nurs; 2003 Apr; 26(2):161-7. PubMed ID: 12660565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
    Van Cutsem E; Verslype C; Tejpar S
    Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine: a new adjuvant option for colorectal cancer.
    Berg DT
    Clin J Oncol Nurs; 2006 Aug; 10(4):479-86. PubMed ID: 16927901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y; Hoff P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer.
    Craven O; Hughes CA; Burton A; Saunders MP; Molassiotis A
    Eur J Cancer Care (Engl); 2013 May; 22(3):413-9. PubMed ID: 23527965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine: an overview of the side effects and their management.
    Saif MW; Katirtzoglou NA; Syrigos KN
    Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
    Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
    J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
    Twelves CJ
    Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.
    Molassiotis A; Brearley S; Saunders M; Craven O; Wardley A; Farrell C; Swindell R; Todd C; Luker K
    J Clin Oncol; 2009 Dec; 27(36):6191-8. PubMed ID: 19917849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine in the management of colorectal cancer.
    Maroun JA
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):327-33. PubMed ID: 12113099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.